![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, Connecticut (S.D., N.M., D.K.D.); Department of Pharmacology, University of Debrecen, Debrecen, Hungary (S.D., A.T.); and Department of Pharmacy, Creighton University, Omaha, Nebraska (D.B.)
Received September 2, 2005; accepted March 7, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
; Sato et al., 2000b; Hattori et al., 2002; Das et al., 2005b). The cardioprotective mechanisms of resveratrol include antioxidant (Ray et al., 1999; Das et al., 2005c), anti-inflammatory (Sato et al., 2000b; Das et al., 2006), and antiplatelet (Bertelli et al., 1996) activities, all of which involve nitric oxide signaling (Chen and Pace-Asciak, 1996; Hattori et al., 2002; Imamura et al., 2002; Das et al., 2005a). Because of close resemblance of the mechanisms of action between ischemic preconditioning (Tosaki et al., 1998; Guo et al., 1999) and resveratrol-mediated cardioprotection (Ray et al., 1999; Hattori et al., 2002; Das et al., 2005b), it has been postulated that resveratrol protects the heart through preconditioning.
Recently, resveratrol was found to protect the ischemic heart through the up-regulation of adenosine A1 and A3 receptors (Das et al., 2005b), a property shared by ischemic preconditioning (Bradamante et al., 2000; Hattori et al., 2002; Imamura et al., 2002; Das et al., 2005b). In this study, resveratrol induced the expression of BclII and caused its phosphorylation along with the phosphorylation of cAMP response element-binding protein (CREB), Akt, and Bad. Phosphatidylinositol 3 kinase inhibitor LY294002 partially blocked the cardioprotective abilities of resveratrol, suggesting that resveratrol transmits a survival signal through a CREB-dependent phosphatidylinositol 3 kinase-Akt-BclII signaling pathway. Subsequent studies determined that such a survival signal through the activation of CREB could also occur through an Akt-independent pathway (Das et al., 2005c).
Ischemic preconditioning, the state-of-the-art techniques of cardioprotection, involves mitogen-activated protein kinase (MAPK) as upstream signaling molecules (Fryer et al., 2001; Baines et al., 2002). Whether resveratrol also transmits survival signals through a signaling cascade involving MAPK is not known. A recent study showed that in mouse epidermal cells, resveratrol activated extracellular signal-regulated kinases (ERK), c-Jun NH2-terminal kinases (JNK), and p38 MAPK, leading to the serine 15 phosphorylation of p53 (She et al., 2001). In this study, pretreatment of the cells with PD98059 or SB-202190 or stable expression of a dominant-negative mutant of ERK2 or p38 kinase impaired resveratrol-induced p53-dependent transcriptional activity and apoptosis, suggesting that both ERK and p38 MAPK mediate resveratrol-induced p53 phosphorylation. The present study was designed to investigate whether, similar to ischemic preconditioning, resveratrol preconditioning also involved MAPK signaling.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Animals
All of the animals used in this study received humane care in compliance with the principles of laboratory animal care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (publication no. NIH 85-23, revised 1985). Sprague-Dawley male rats weighing between 250 and 300 g were fed ad libitum regular rat chow with free access to water until the start of the experimental procedure. The rats were randomly assigned to one of the following groups (Fig. 1), perfused for 15 min with Krebs-Henseleit bicarbonate (KHB); 1) vehicle (DMSO) only, 2) PD98059 only, 3) SB-202190 only, 4) H89 only, 5) KT5720 only, 6) KHB containing 10 µM resveratrol, 7) 10 µM resveratrol + 20 µM PD98059, 8) 10 µM resveratrol + 10 µM SB-202190, 9) 10 µM resveratrol + 1 µM H89, or 10) 10 µM resveratrol + 10 µM KT5720. All of the hearts were then subjected to 30 min of ischemia, followed by 2 h of reperfusion.
|
Isolated Working Heart Preparation
Rats were anesthetized with sodium pentobarbital (80 mg/kg i.p.) (Abbott Laboratories, North Chicago, IL) and an anticoagulant with heparin sodium (500 IU/kg i.v.) (Elkins-Sinn Inc., Cherry Hill, NJ). After ensuring sufficient depth of anesthesia, thoracotomy was performed, and hearts were perfused in the retrograde Langendorff mode at 37°C at a constant perfusion pressure of 100 cm of water (10 kPa) for a 5-min washout period. The perfusion buffer used in this study consisted of a modified KHB (118 mM sodium chloride, 4.7 mM potassium chloride, 1.7 mM calcium chloride, 25 mM sodium bicarbonate, 0.36 mM potassium biphosphate, 1.2 mM magnesium sulfate, and 10 mM glucose). The Langendorff preparation was switched to the working mode after the washout period as described previously (Engelman et al., 1995).
At the end of 10 min, after the attainment of steady-state cardiac function, baseline functional parameters were recorded. The circuit was then switched back to the retrograde mode, and hearts were perfused with either KHB with vehicle (DMSO) or any of the blockers (control), resveratrol at a concentration of 10 µM, or a combination of resveratrol and the any of the blockers for 15 min. This was followed by a 5-min washout with KHB buffer, and then the hearts were subjected to global ischemia for 30 min and 2 h of reperfusion. The first 10 min of reperfusion was in the retrograde mode to allow for postischemic stabilization and thereafter in the antegrade working mode to allow for assessment of functional parameters, which were recorded at 10-, 30-, 60-, and 120-min reperfusion.
Cardiac Function Assessment
Aortic pressure was measured using a Gould P23XL pressure transducer (Gould Instrument Systems Inc., Valley View, OH) connected to a side arm of the aortic cannula, and the signal was amplified using a Gould 6600 series signal conditioner and monitored on a CORDAT II real-time data acquisition and analysis system (Triton Technologies, San Diego, CA). Heart rate, left ventricular developed pressure (LVDP) (defined as the difference of the maximum systolic and diastolic aortic pressures), and the first derivative of developed pressure (dP/dT) were all derived or calculated from the continuously obtained pressure signal. Aortic flow was measured using a calibrated flowmeter (Gilmont Instrument Inc., Barrington, IL), and coronary flow was measured by timed collection of the coronary effluent dripping from the heart.
Infarct Size Estimation
At the end of reperfusion, the left ventricle was cut into transverse slices. The slices were incubated in 1% triphenyl tetrazolium solution in phosphate buffer (88 mM Na2HPO4 and 1.8 mM NaH2PO4) for 20 min at 37°C. This procedure distinguishes necrotic tissue from viable myocardium. The slices were stored for 48 h in 10% buffered formalin. The heart slices were photographed, and the weights of the slices were monitored. Digital images of the slices were magnified, and the area of necrosis in each slice was quantified by computerized planimetry. The risk and infarct volumes in cubic centimeters of each slice were then calculated based on the slice weight to remove the introduction of any errors caused by nonuniformity of heart slice thickness. The risk volumes and infarct volumes of each slice were summed to obtain the risk and infarct volumes for the whole heart. Infarct size was taken to be the percent infarct volume of risk volume for any one heart.
Terminal Deoxynucleotidyl Transferase dUTP Nick-End Labeling Assay for Assessment of Apoptotic Cell Death
Immunohistochemical detection of apoptotic cells was carried out using terminal deoxynucleotidyl transferase dUTP nick-end labeling (Maulik et al., 2000). The sections were incubated again with mouse monoclonal antibody recognizing cardiac myosin heavy chain to specifically recognize apoptotic cardiomyocytes. The fluorescence staining was viewed with a confocal laser microscope. The number of apoptotic cells was counted and expressed as a percentage of total myocyte population.
Western Blot Analysis. Left ventricles from the hearts were homogenized in a buffer containing 25 mM Tris-HCl, 25 mM NaCl, 1 mM orthovanadate, 10 mM NaF, 10 mM pyrophosphate, 10 µM okadaic acid, 0.5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride (Sato et al., 2000a). One hundred micrograms protein of each heart homogenate was incubated with 1 µg of antibody against the phospho-CREB, p38 MAPK, MSK-1, and MAPK-activated protein (MAPKAP) kinase 2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 h at 4°C. The immune complexes were precipitated with protein A-Sepharose, and the immunoprecipitates were separated by SDS-polyacrylamide gel electrophoresis and immobilized on polyvinylidene difluoride membrane. The membrane was immunoblotted with PY20 to evaluate the phosphorylation of the compounds. The membrane was stripped and reblotted with specific antibodies against CREB, p38 MAPK, MSK-1, and MAPKAP kinase 2. The resulting blots were digitized and subjected to densitometric scanning using a standard NIH image program.
Statistical Analysis
The values for myocardial functional parameters, total and infarct volumes and infarct sizes, and cardiomyocyte apoptosis are all expressed as the mean ± S.E.M. Analysis of variance test was first carried out to test for any differences between the mean values of all the groups. If differences were established, the values of the treated groups were compared with those of the control group by a modified t test. The results were considered significant if p < 0.05.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). There was no effect on myocardial infarct size in any of these doses of resveratrol (Fig. 3). Consistent with previously published articles, the maximum beneficial effect was noticed at 10 µM resveratrol. At a higher dose (25 µM), resveratrol still exerts cardioprotective effects, but the effects tend to be slightly depressed. Subsequent studies were performed with 10 µM resveratrol.
|
|
|
|
Effects of Resveratrol on Myocardial Infarct Size. Infarct size (percentage of infarct versus total area at risk) was noticeably reduced in the resveratrol group compared with the control group (18.17 ± 2.08 versus 34.7 ± 2.74%) (Fig. 6, top). This infarct zone was increased significantly when resveratrol was used along with SB-202190 and PD98059 (30.4 ± 2.44 and 29.8 ± 1.98%, respectively, versus 18.17 ± 2.08%). When resveratrol was used along with H89, the infarct zone was further increased compared with the other two inhibitors (33.6 ± 2.62%) as shown in Fig. 6, top. KT5720 did not have any effect on infarct size-lowering ability of resveratrol.
|
Effects of Resveratrol on the Phosphorylation of p38 MAPK, MAPKAP Kinase 2, MSK-1, and CREB. The dose-response curve for the activation and phosphorylation of ERK1/2, p38 MAPK, and Akt is shown in Fig. 7. There was no activation of any of the kinases (Fig. 7, black bars); however, at both 10 and 25 µM, increased phosphorylation of ERK1/2, p38 MAPK, and Akt occurred (Fig. 7, white bars). Resveratrol at 3.7 and 7.4 µM concentrations could not induce phosphorylation of any of these kinases. Our subsequent studies were performed with 10 µM resveratrol concentration.
|
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Inverse relationship between the consumption of red wine and incidence of cardiovascular disease has been popularly known as the French paradox (Kopp, 1998). The cardioprotective abilities of red wine have been attributed to resveratrol (Kopp, 1998; Hung et al., 2000), which possesses diverse properties, including anti-inflammatory, antiplatelet, and vasorelaxant activities (Bertelli et al., 1996; Sato et al., 2000b; Orallo et al., 2002). Striking similarities of the cardioprotective properties between resveratrol and nitric oxide (NO) prompted the researcher to determine the role of NO in resveratrol-mediated cardioprotection. A direct role of NO was shown from a study, which found resveratrol-mediated increase in nitric-oxide synthase (NOS) activity in cultured pulmonary artery endothelial cells, suggesting that resveratrol could afford cardioprotection by affecting the expression of NOS (Hsieh et al., 1999). Consistent with these results, resveratrol was found to protect isolated working rat hearts through the up-regulation of iNOS (Hattori et al., 2002; Das et al., 2005a). Resveratrol failed to provide cardioprotection in iNOS knockout mice devoid of any copy of iNOS gene, further supporting the role of NO (Imamura et al., 2002). In a more recent study, resveratrol reduced myocardial ischemia/reperfusion injury in both an iNOS-dependent and iNOS-independent manner (Hung et al., 2004). Similar to NO, resveratrol significantly reduced the amount of proadhesive molecules, including soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1, and E-selectin, in the ischemic reperfused myocardium (Das et al., 2006).
Resveratrol has been known to modulate MAPK signaling. Among the three MAPK, ERK1/2 is involved in cell proliferation, whereas p38 MAPK and JNK are activated in response to environmental stress. In undifferentiated cells, a small amount (1 µM) of resveratrol can induce phosphorylation of ERK1/2 (Miloso et al., 1999). In retinoic acid-differentiated cells, the same amount of resveratrol induced an increase in ERK1/2 phosphorylation. Another study showed increased phosphorylation of ERK1/2, JNK, and p38 MAPK in the mouse epidermal cells, which subsequently enhanced serine 15 phosphorylation of p53 (She et al., 2001). Dominant-negative mutant of ERK2 or p38 MAPK depressed phosphorylation of p53 at serine 15. In this study, overexpression of dominant-negative mutant of JNK1 had no effect on this phosphorylation. In papillary and follicular thyroid carcinoma cell lines, a relatively higher amount of resveratrol (1–10 mM) induced activation and nuclear translocation of ERK1/2 (Shih et al., 2002). Interestingly, at higher concentrations (even at 50–100 µM), resveratrol seems to inhibit phosphorylation of MAPK. At 37 mM concentration, resveratrol depressed MAPK activity and reduced phosphorylation of ERK1/2, JNK1, and p38 MAPK at active sites (El-Mowafy and White, 1999). Another related study showed that resveratrol activated JNK at the same dose that inhibited tumor promoter-induced cell transformation (She et al., 2002). Thus, it seems that resveratrol can cause activation of MAPK in some cells, whereas it inhibits MAPK in others. Moreover, activation/inhibition seems to be concentration-dependent; in general, it is stimulatory at lower concentration and inhibitory at higher concentration. In the present study, resveratrol at 10 µM concentrations enhanced the phosphorylation of p38 MAPK and ERK1/2. In concert, inhibition of p38 MAPK with SB-202190 or ERK1/2 with PD98059 partially abolished the effect of preconditioning. MSK-1 is situated downstream of ERK1/2 and p38 MAPK (Fig. 10). MSK-1, which belongs to the AGC family of kinases and is related in structure to the ribosomal p70 S6 subfamily, can be activated by both ERK1/2 and p38 MAPK (Fig. 7). MSK-1, as well as MSK-2, can be directly activated both in vitro and in vivo by p42/44 ERK and p38 MAPK in cultured cells (Deak et al., 1998). In another study, MSK-1 and MSK-2 activities were increased 400 to 500% and 200 to 300%, respectively, in exercised muscle along with an increase in MAPKAP kinase 2 (Krook et al., 2000). In a related study, ERK1/2 phosphorylation increased 7.8-fold and p38 MAPK phosphorylation increased 4.4-fold after the exercise. The activity of MAPKAP kinase 2, the downstream target of p38 MAPK, increased 3.1-fold, whereas MSK-1, downstream of both ERK1/2 and p38 MAPK, increased 2.4-fold at the same time. In the present study, resveratrol-mediated increase in MSK-1 seems to be the result of the activation of both p38 MAPK and ERK1/2 because inhibition of either p38 MAPK or ERK1/2 resulted in partial down-regulation of MSK-1.
|
MSK-1 is required for CREB and the closely related activating transcription factor activation after mutagenic or stress stimuli. On phosphorylation, they recruit the coactivator CREB-binding protein, thereby effecting phosphorylation. Recently, resveratrol was found to phosphorylate CREB via adenosine A1 and A3 receptors through the activation of Akt survival pathway (Das et al., 2005b). Another related study showed activation of CREB by resveratrol through Akt-dependent and Akt-independent pathways (Das et al., 2005c). Several distinct pathways can induce CREB, which is an important nuclear factor for cell survival. For example, growth factors and stress can induce CREB phosphorylation through the activation of downstream targets of MAPK signaling pathways, including classical ERK pathway and stress-activated p38 MAPK pathway (Shaywitz and Greenberg, 1999). Recent studies determined that MSK are the major growth factor-regulated CREB kinase (Wiggin et al., 2002). In the present study, resveratrol-mediated CREB activation seems to occur through the phosphorylation of MSK-1 because the inhibition of MSK-1 abolished the phosphorylation of CREB. Previous studies showed the involvement of CREB in transmitting resveratrol-mediated survival signal through the activation of BclII (Das et al., 2005b). Thus, it seems that resveratrol activates CREB through the phosphorylation of MSK-1.
In this study, 1 µM H89 was used to block MSK activation. However, this compound can also block PKA. A recent study showed that 2 µM H89 enhanced postischemic cardiac contractile recovery and reduced infarct size (Makaula et al., 2005), presumably by reducing PKA activity. To confirm the role of MSK signaling in resveratrol preconditioning, the hearts were also treated with a specific PKA blocker, KT5720, in conjunction with resveratrol. Unlike H89, which abolished resveratrol-mediated cardioprotection, KT5720 did not alter resveratrol-mediated ventricular recovery, nor did it have any effect on infarct size-lowering ability of resveratrol. Western blot analysis revealed that KT5720 did not affect the phosphorylation of MSK or CREB induced by resveratrol. These results confirmed that MSK signaling was involved in resveratrol preconditioning.
MAPKAP kinase 2 is the downstream target for p38 MAPK. A large number of reports exist in the literature indicating that MAPKAP kinase 2 plays a crucial role in preconditioning (Maulik et al., 1999). Preconditioning potentiates the phosphorylation of p38 MAPK, leading to the phosphorylation of MAPKAP kinase 2, which in turn up-regulates heat shock protein 27 (Chevalier and Allen, 2000). In this study, resveratrol could phosphorylate MAPKAP kinase 2 via the activation of p38 MAPK because the MAPKAP kinase 2 phosphorylation was partially blocked with SB-202190.
In summary, the results of the present study showed for the first time that resveratrol triggers a preconditioning-like survival signaling by activating MAPK signaling pathway. Thus, resveratrol activates both ERK1/2 and p38 MAPK, both of which contribute toward the phosphorylation of MSK-1. There seems to be two downstream targets for p38 MAPK, MSK-1 and MAPKAP kinase 2. MSK-1 in turn activates CREB, which was previously shown to transmit survival signal by activating BclII.
|
Footnotes |
|---|
ABBREVIATIONS: CREB, cAMP response element-binding protein; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride; MAPK, mitogen-activated protein kinase(s); ERK, extracellular signal-regulated kinase(s); JNK, c-Jun NH2-terminal kinase(s); PD98059, 2'-amino-3'-methoxyflavone; SB-202190, 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; H89, N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline; PKA, protein kinase A; KT5720, (9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl ester; MSK-1, mitogen- and stress-activated protein kinase 1; DMSO, dimethyl sulfoxide; KHB, Krebs-Henseleit bicarbonate; LVDP, left ventricular developed pressure; dP/dT, maximum first derivative of developed pressure; R, reperfusion; MAPKAP, mitogen-activated protein kinase-activated protein; NO, nitric oxide; NOS, nitric-oxide synthase; iNOS, inducible nitric-oxide synthase.
Address correspondence to: Dipak K. Das, Cardiovascular Research Center, University of Connecticut, School of Medicine, Farmington, CT 06030. E-mail: ddas{at}neuron.uchc.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, and Ping P (2002) Mitochondrial PKC
and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKC-MAPK interactions and differential MAPK activation in PKC-induced cardioprotection. Circ Res 90: 390–397.
Bertelli AA, Giovannini L, Bernini W, Migliori M, Fregoni M, Bavaresco L, and Bertelli A (1996) Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 22: 61–63.[Medline]
Bradamante S, Piccinini F, Barenghi L, Bertelli AA, De Jonge R, Beemster P, and De Jong JW (2000) Does resveratrol induce pharmacological preconditioning? Int J Tissue React 22: 1–4.[Medline]
Chen CK and Pace-Asciak CR (1996) Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 27: 363–366.[Medline]
Chevalier D and Allen BG (2000) Two distinct forms of MAPKAP kinase-2 in adult cardiac ventricular myocytes. Biochemistry 39: 6145–6156.[CrossRef][Medline]
Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, and Das DK (2005a) Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 42: 281–289.[CrossRef][Medline]
Das S, Bertelli AA, Bertelli A, Maulik N, and Das DK (2006) Anti-inflammatory action of resveratrol: a novel mechanism of action. Drugs Exp Clin Res, in press.
Das S, Cordis GA, Maulik N, and Das DK (2005b) Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol 288: H328–H335.
Das S, Tosaki A, Bagchi D, Maulik N, and Das DK (2005c) Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther 314: 762–769.
Deak M, Clifton A, Lucocq L, and Alessi D (1998) Mitogen- and stress-activated protein kinase-1 (MSK-1) is directly activated by MAPK and SAPK/p38 and may mediate activation of CREB. EMBO (Eur Mol Biol Organ) J 15: 4426–4441.[CrossRef]
El-Mowafy AM and White RE (1999) Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett 451: 63–67.[CrossRef][Medline]
Engelman DT, Watanabe M, Engelman RM, Rousou JA, Kisin E, Kagan VE, Maulik N, and Das DK (1995) Hypoxic preconditioning preserves antioxidant reserve in the working rat heart. Cardiovasc Res 29: 133–140.[CrossRef][Medline]
Fryer RM, Pratt PF, Hsu AK, and Gross GJ (2001) Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther 296: 642–649.
Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, et al. (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96: 11507–11512.
Hattori R, Otani H, Maulik N, and Das DK (2002) Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol 282: H1988–H1995.
Hsieh TC, Juan G, Darzynkiewicz Z, and Wu JM (1999) Resveratrol increases nitric oxide synthetase, induces accumulation of p53 and p21 (WAF1/CIPI) and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 59: 2596–2601.
Hung LM, Chen JK, Huang SS, Lee RS, and Su MJ (2000) Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47: 549–555.
Hung LM, Su MJ, and Chen JK (2004) Resveratrol protects myocardial ischemia reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med 36: 774–781.[CrossRef][Medline]
Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, and Das DK (2002) Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol 282: H1996–H2003.
Kopp P (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the `French paradox'? Eur J Endocrinol 138: 619–620.[CrossRef][Medline]
Krook A, Widegren U, Jiang XJ, Henriksson J, Wallberg-Henriksson H, Alessi D, and Zierath JR (2000) Effects of exercise on mitogen- and stress-activated kinase signal transduction in human skeletal muscle. Am J Physiol 279: R1716–R1721.
Makaula S, Lochner A, Genade S, Sack MN, Awan MM, and Opie LH (2005) H-89, a non-specific inhibitor of protein kinase A, promotes post-ischemic cardiac contractile recovery and reduces infarct size. J Cardiovasc Pharmacol 45: 341–347.[CrossRef][Medline]
Maulik N, Engelman RM, Rousou JA, Flack JE 3rd, Deaton D, and Das DK (1999) Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 100: II369–II375.
Maulik N, Sasaki H, Addya S, and Das DK (2000) Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett 485: 7–12.[CrossRef][Medline]
Miloso M, Bertelli AA, Nicolini G, and Tredici G (1999) Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci Lett 264: 141–144.[CrossRef][Medline]
Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, and Fernandez P (2002) The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 61: 294–302.
Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, and Das DK (1999) The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 27: 160–169.[CrossRef][Medline]
Sato M, Cordis GA, Maulik N, and Das DK (2000a) SAPKs regulation of ischemic preconditioning. Am J Physiol 279: H901–H907.
Sato M, Maulik G, Bagchi D, and Das DK (2000b) Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic Res 32: 135–144.[Medline]
Shaywitz AJ and Greenberg ME (1999) CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821–861.[CrossRef][Medline]
She QB, Bode AM, Ma WY, Chen NY, and Dong Z (2001) Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61: 1604–1610.
She QB, Huang C, Zhang Y, and Dong Z (2002) Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 33: 244–250.[CrossRef][Medline]
Shih A, Davis FB, Lin HY, and Davis PJ (2002) Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab 87: 1223–1232.
Tosaki A, Maulik N, Elliott GT, Blasig IE, Engelman RM, and Das DK (1998) Preconditioning of rat heart with monophosphoryl lipid A: a role for nitric oxide. J Pharmacol Exp Ther 285: 1274–1279.
Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, and Arthur JS (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22: 2871–2881.
This article has been cited by other articles:
|
|
 |
|
  A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1236 - H1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lekli, G. Szabo, B. Juhasz, S. Das, M. Das, E. Varga, L. Szendrei, R. Gesztelyi, J. Varadi, I. Bak, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H859 - H866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Das, I. Lekli, M. Das, G. Szabo, J. Varadi, B. Juhasz, I. Bak, K. Nesaretam, A. Tosaki, S. R. Powell, et al. Cardioprotection with palm oil tocotrienols: comparision of different isomers Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H970 - H978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagaoka, T. W. Hein, A. Yoshida, and L. Kuo Resveratrol, a Component of Red Wine, Elicits Dilation of Isolated Porcine Retinal Arterioles: Role of Nitric Oxide and Potassium Channels Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4232 - 4239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moritz, R. Gust, and H. H. Pertz Characterization of the Relaxant Response to N,N'-Dipropyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine in Porcine Coronary Arteries J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
, p < 0.05 versus resveratrol.
), and the nonphosphorylated proteins are shown in white bars (
). The average of three experiments (mean ± S.E.M.) is shown as bar graphs.
